Equities Analysts Offer Predictions for IGC Pharma FY2026 Earnings

IGC Pharma, Inc. (NYSEAMERICAN:IGC) – Stock analysts at Ascendiant Capital Markets issued their FY2026 earnings estimates for IGC Pharma in a research report issued to clients and investors on Tuesday, August 25th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will earn ($0.10) per share for the year. Ascendiant Capital Markets currently has a “Buy” rating and a $5.50 target price on the stock. The consensus estimate for IGC Pharma’s current full-year earnings is ($0.10) per share. Ascendiant Capital Markets also issued estimates for IGC Pharma’s FY2027 earnings at ($0.08) EPS.

IGC Pharma (NYSEAMERICAN:IGC) last released its earnings results on Friday, August 14th. The company reported ($0.03) earnings per share for the quarter. The company had revenue of $0.27 million during the quarter.

Separately, Zacks Research raised shares of IGC Pharma to a “hold” rating in a report on Friday, August 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.50.

IGC Pharma Stock Down 0.8%

Shares of IGC stock opened at $0.30 on Monday. IGC Pharma has a one year low of $0.23 and a one year high of $0.47. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.39 and a quick ratio of 0.19. The stock has a fifty day moving average price of $0.27 and a 200 day moving average price of $0.28. The stock has a market cap of $30.67 million, a P/E ratio of -4.24 and a beta of 0.48.

Institutional Investors Weigh In On IGC Pharma

A number of hedge funds have recently made changes to their positions in IGC. State Street Corp boosted its position in IGC Pharma by 25.3% in the fourth quarter. State Street Corp now owns 200,799 shares of the company’s stock valued at $57,000 after buying an additional 40,592 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of IGC Pharma by 131.7% during the third quarter. Citadel Advisors LLC now owns 627,840 shares of the company’s stock worth $262,000 after buying an additional 356,874 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of IGC Pharma by 91.0% during the third quarter. Virtu Financial LLC now owns 89,546 shares of the company’s stock worth $37,000 after buying an additional 42,654 shares in the last quarter. Institutional investors and hedge funds own 3.87% of the company’s stock.

About IGC Pharma

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc and changed its name to IGC Pharma, Inc in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.